clinical trial · NCT04767802
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Polycythemia VeraPTG-300
brief summary
This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit \>48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks to maintain hematocrit \<45% with a target of \<43%. Subjects may receive PTG-300 treatment for up to 52 weeks.
started
Feb 2, 2021
primary completion
Mar 15, 2023
completion
Mar 15, 2023
last updated
Mar 18, 2024
official title
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol